Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04709692Phase 2Completed

Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

Role: collaborator

NCT03377777Completed

The Effect of Anemia in Infancy on the Microbiome and Systemic Metabolism

Role: collaborator

NCT02123290Phase 2Completed

DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax

Role: collaborator

NCT01314937Phase 4Completed

The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas

Role: collaborator

All 4 trials loaded